Opfolda

Opfolda contains miglustat, an oral enzyme stabilizer designed to support adults living with late‑onset Pompe disease, a rare genetic condition caused by deficiency of the enzyme acid alpha‑glucosidase (GAA). In this disorder, glycogen — a stored form of sugar — builds up in muscle cells, leading to progressive muscle weakness, breathing difficulties, and reduced mobility. Opfolda is taken in combination with cipaglucosidase alfa, an enzyme therapy that helps break down accumulated glycogen, and works by binding and stabilizing the enzyme in the bloodstream so more reaches muscle cells and remains active longer.
Late‑onset Pompe disease can affect skeletal muscles and the muscles that support respiration. By helping cipaglucosidase alfa remain stable and effective, Opfolda contributes to improved muscle function and overall physical capacity in adults who have not shown sufficient improvement with enzyme therapy alone. Clinical studies have demonstrated meaningful gains in walking distance and respiratory support measures when Opfolda is used alongside enzyme therapy compared with standard approaches.
Opfolda is supplied as oral capsules and is typically taken on an empty stomach before enzyme therapy sessions. Because it interacts with enzyme replacement treatment, coordinated timing of doses is important.
Common effects associated with the combination include headache, diarrhea, tiredness, nausea, abdominal discomfort, and fever. These responses are generally manageable, but any persistent or severe symptoms should be discussed with a healthcare professional.
Proper management of late‑onset Pompe disease also involves multidisciplinary care, physical therapy, and regular monitoring of muscle and respiratory function. When paired with comprehensive supportive measures, Opfolda’s stabilization of enzyme activity plays a key role in helping adults with this condition maintain strength, mobility, and quality of life.